Leni van Doorn

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

F. Eskens, Constantijne H. Mom, André Planting et al. · British Journal of Cancer · 2007 · 231 citations · Full text

Medicine, Oncology, Pharmacology +17

Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors

Ferry A.L.M. Eskens, Maja J.A. de Jonge, Pankaj Bhargava et al. · Clinical Cancer Research · 2011 · 108 citations · Full text

Medicine, Oncology, Pharmacology +17

Aggressive angiomyxoma: multimodality treatments can avoid mutilating surgery

I. J. M. Han‐Geurts, Albertus N. van Geel, Leni van Doorn et al. · European Journal of Surgical Oncology · 2006 · 101 citations

Medicine, Oncology, Surgery +4

Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours

Jos Kitzen, Maja J.A. de Jonge, C. B. H. W. Lamers et al. · European Journal of Cancer · 2009 · 90 citations

Life Sciences, Oncology, Pharmacology +14

The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation

Martijn P. Lolkema, Hilde Bohets, Hendrik‐Tobias Arkenau et al. · Clinical Cancer Research · 2015 · 83 citations · Full text

Medicine, Pharmacology, Toxicology +17